Waiv

Waiv partners with biopharma to develop AI biomarkers and companion diagnostics on routine H&E and IHC slides, from biomarker discovery to an approved CDx.

Co-develop an AI diagnostic with Waiv: model fine-tuning, a go/no-go decision, product development and validation, then global rollout.

Waiv's AI screening on routine H&E slides helps biopharma cut diagnostic testing costs, recruit eligible patients sooner and keep trials on schedule.

Waiv's open pathology foundation models are trained to capture tissue biology rather than scanner or staining differences, giving consistent results from one lab to the next.

Published in npj Precision Oncology: a 1,025-patient study of BRCAura, a research-use-only AI model estimating germline BRCA1/2 status from routine H&E slides.

Published science on how RlapsRisk BC uses AI to help identify breast cancer patients at risk of relapse, supporting doctors in making more precise treatment decisions.

Waiv CEO and Co-Founder Meriem Sefta discussed the company’s origins as an Owkin project and its evolution into an independent business on the Base to Base Biotech podcast.

Foundation models are rapidly reshaping computational pathology, but comparing their performance across studies remains difficult. Enter Histoboard: a living platform that aggregates published benchmark results to help researchers and clinicians navigate this evolving landscape.

Waiv’s AI diagnostic tests integrate into digital pathology workflows to assist pathologists with accurate, timely diagnoses.

Owkin announced that it has entered into a collaboration agreement with MSD to develop and commercialize AI-powered digital pathology diagnostics for the EU market.

Owkin and AstraZeneca partnered to develop an AI tool for pre-screening gBRCAm in breast cancer using digitized pathology slides.

The Waiv leadership team includes clinicians, scientists, and builders focused on advancing precision medicine.

Waiv converts routine pathology slides into clinical-grade precision tests for cancer.

Waiv offers products, demos, and research updates.

Catalyzing precision medicine with AI-enabled tests that accelerate biomarker discovery & detection, outcome prediction, and treatment-response assessment across oncology.

Waiv describes how it processes patient data for research and validation projects.